{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 48,
  "pageCount": 53,
  "prevPage": 47,
  "nextPage": 49,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/48",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-48",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.91,
        "x": 0.058,
        "y": 0.00185
      },
      "kind": "list",
      "text": "Phase 2 Part A New Data: Dose related exposure, reductions in body sway/heart rate\nOngoing Phase 2 Part B: 2 cohorts completed – 10 mg and 30 mg doses reduced THC-related effects despite a higher THC dose, appears safe and well tolerated\nPlans for Completion of Part B: Cohort 3 ongoing using staggered dosing – 3 more cohorts currently planned for PK/PD modeling\nRegulatory Update: Next FDA/MIDD meeting in November\nPlanned First US Clinical Study: Observational study in ACI patients\nPath to Potential Approval: To be finalized after Phase 2 study is completed\nParenteral Product: Prototype formulations in development for preclinical testing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "feb2581d-caf7-4cf1-b0cb-070f51043994",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.095,
        "w": 0.778,
        "x": 0.038,
        "y": 0.045
      },
      "kind": "title",
      "text": "ANEB-001 Clinical Development for ACI - Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "435a0852-ee1d-4c18-825f-90d067de8555",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "bb4c6c01-7daf-4209-82cf-b991b35e51ce",
      "evidence": "This slide is titled 'ANEB-001 Clinical Development for ACI - Summary' and contains a summary of clinical development data.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}